SLNO
Soleno Therapeutics, Inc.
5-year outlook
$39.49
Delayed data
Outlook profile
High upside
For information only — not financial advice.
Five-year outlook
Fair values and forward P/E anchor the model; bear, base, and bull show implied annual returns if price moved to each fair-value anchor over five years.
Fair value & forward multiple
DCF Value
$343.84
Saved valuation
770.7% margin
MarketSnap Value
$142.89
Pre-calculated + market intelligence
261.8% margin
Forward P/E (5Y)
2.76×
Price ÷ year-5 avg EPS estimate
Illustrative $10,000 after 5 years
| Scenario | Value in 5 years | CAGR |
|---|---|---|
| Bear | $25,617 | +20.70% |
| Base | $36,184 | +29.33% |
| Bull | $60,840 | +43.50% |
Figures are rough annualized paths to our bear, base, and bull value anchors — not a prediction of yearly returns.
Bear, base & bull paths (CAGR)
Bear
20.7%
CAGR
Base
29.33%
CAGR
Bull
43.5%
CAGR
Financial quality
Overall 56/100
- Profitability Moderate
- Balance sheet Strong
- Cash flow stability Weak
- Shareholder dilution High
- Business predictability Strong
Investment style fit
Best suited for
Data confidence
Log in for full outcome drivers, what must go right, what can go wrong, AI Reality Check, and personalized valuation tools.
Log in to continue
Log in to see the full 5-year outlook — drivers, risks, AI tools, and your saved valuations.
Login — it's free